Peptide Field Reference

Retatrutide

Triple-agonist GLP-1/GIP/Glucagon — the most powerful weight loss peptide ever studied.

Looking to buy retatrutide in the Philippines? This page covers the molecule itself — Phase 3 dosing, mechanism, and trial results. For Philippines-specific sourcing, legal status, and supplier verification, read the 2026 guide. Read the Retatrutide Philippines 2026 guide →

What is Retatrutide

Retatrutide is a novel triple-agonist peptide developed by Eli Lilly that simultaneously activates three metabolic receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. This triple-action mechanism makes it the most potent weight loss compound ever studied in clinical trials.

In a Phase 2 trial published in the New England Journal of Medicine (2023), participants on the highest dose (12mg) achieved an average body weight reduction of 28.7% over 48 weeks — more than double the effect of early GLP-1 drugs. This has made Retatrutide highly sought after in the biohacking and weight loss communities, including in the Philippines.

While not yet FDA approved (currently in Phase 3 trials), research-grade retatrutide is widely available through peptide suppliers. Users consistently report dramatic fat loss with good tolerability, particularly compared to semaglutide. Browse all weight loss peptide options to compare, or verify your supplier with the COA verification guide.

§ 02

How it works

GLP-1 Agonism: Activates GLP-1 receptors in the brain and pancreas to suppress appetite, slow gastric emptying, and improve insulin secretion. This is the same mechanism as Ozempic and Mounjaro.

GIP Agonism: Activates GIP receptors which synergize with GLP-1 to enhance insulin response and are thought to reduce the nausea commonly associated with GLP-1 drugs alone.

Glucagon Agonism: This is what makes Retatrutide unique. Glucagon agonism directly increases metabolic rate (thermogenesis) and enhances fat oxidation — particularly visceral fat. This explains the superior weight loss results compared to dual-agonists.

Retatrutide in the Philippines

Retatrutide is not commercially available in the Philippines — Eli Lilly's Phase 3 trials are still in progress and no branded product is FDA Philippines-registered. Every retatrutide protocol running in Manila, Makati, BGC, or Cebu in 2026 is research-grade. There is no Mercury Drug or Watsons option for this compound.

The research-grade route runs through the same supplier network that ships semaglutide and tirzepatide. Cold-chain handling is the most critical of the three GLP-class peptides — retatrutide degrades faster at room temperature, so insulated overnight delivery from a verified local supplier is the only sensible route. Lalamove same-day with a hard-sided cooler is the standard.

Self-directed retatrutide protocols in the Philippines are typically guided by a Salcedo or Legazpi wellness clinic doctor for bloodwork and dose review, even though the prescription itself does not exist. Expect to pay PHP 4,500–8,000 per consult for a doctor with peptide-specific clinical experience. Bloodwork (CBC, CMP, lipid panel, HbA1c) at Hi-Precision or Healthway runs PHP 3,500–5,500.

Hospitals · prescription routes

Makati Medical Center — endocrinologyMakatiBloodwork and clinical review only; will not prescribe research compounds
St. Luke's Medical Center BGC — wellness medicineBGCSome MDs review research peptide protocols informally; no prescription possible
Hi-Precision DiagnosticsMulti-cityStandard pre/post bloodwork; covers Metro Manila, Cebu, Davao

Pharmacies · branches with confirmed stock

Not applicable — no retail availability—Retatrutide is Phase 3 only; research-grade is the only Philippines route

Real PH pricing · observed

Research-grade retatrutide 10mg vial₱5,500–8,500$98–152Local supplier with COA, May 2026
Research-grade retatrutide 30mg vial₱14,500–19,500$260–350Bulk pricing, May 2026
Wellness clinic consult (peptide-experienced MD)₱4,500–8,000$80–143Salcedo / Legazpi cluster
Pre/post bloodwork panel₱3,500–5,500$63–98Hi-Precision / Healthway

Customs · Import reality

Retatrutide research-grade is treated identically to semaglutide and tirzepatide by BOC — personal-use research quantities are tolerated, commercial quantities are not. Because no branded product exists, customs is unlikely to recognize the compound name; suppliers typically ship invoiced as "research peptide" rather than by chemical name. Cold-chain failures during BOC inspection are the most common loss mode — verify your supplier's reshipment policy before ordering.

§ 03

Reported benefits

0128.7% average body weight reduction in Phase 2 trials (highest ever recorded)
02Significant visceral fat reduction due to glucagon receptor activation
03Improved insulin sensitivity and metabolic health markers
04Reduced appetite and food cravings (often dramatically so)
05Possible improvements in cardiovascular risk factors
06Once-weekly dosing for convenience
07Reported reduction in "food noise" — obsessive thoughts about eating

§ 04

Dosing protocol

Suggested titration
Phase	Dose	Frequency	Duration
Starting	2mg	Once weekly	Weeks 1–4
Titration 1	4mg	Once weekly	Weeks 5–8
Titration 2	8mg	Once weekly	Weeks 9–16
Maintenance	8–12mg	Once weekly	Ongoing

Always start at the lowest effective dose and titrate up gradually.

§ 05

Side effects

Common

Nausea (most common, especially when titrating up)
Vomiting (usually resolves with slower titration)
Decreased appetite
Diarrhea or constipation
Fatigue in first few weeks
Injection site reactions (redness, bruising)

Rare

·Pancreatitis (discontinue immediately if severe abdominal pain)
·Gallbladder issues
·Heart rate increase
·Hair loss (associated with rapid weight loss, not the peptide itself)

§ 06

Who should not use Retatrutide

§ 07

What to expect

Week 1–2

Nausea is common as your body adjusts. Appetite begins to decrease. Some report feeling full very quickly after eating small amounts.

Week 3–4

Nausea typically subsides. Food noise begins to quiet. First noticeable weight loss (often 1–3kg) from caloric restriction.

Month 2–3

Steady weight loss continues (typically 1–2kg/week when combined with modest dietary improvements). Energy often improves.

Month 4+

Most users report being at or near their maintenance phase. Weight loss slows as body composition improves. Visceral fat reduction becomes visible.

§ 08

FAQ

Q-01

Is Retatrutide legal in the Philippines?

Retatrutide exists in a gray area. It is not approved as a pharmaceutical in the Philippines, but personal-use importation is not explicitly prohibited. Most users obtain it through research peptide suppliers. For current legal status, sourcing options, and COA red flags specific to Philippines, see the Retatrutide Philippines 2026 guide. Always consult a healthcare professional.

Q-02

How does Retatrutide compare to Tirzepatide?

Retatrutide adds glucagon agonism on top of the GLP-1+GIP mechanism of Tirzepatide, which drives additional metabolic rate increase and fat oxidation. Clinical trials show roughly 6–8% more weight loss with Retatrutide vs Tirzepatide at comparable doses.

Q-03

Do I need to diet while using Retatrutide?

The appetite suppression is so strong that most users naturally eat less without consciously dieting. However, maintaining protein intake (1.6g/kg bodyweight) is critical to prevent muscle loss during rapid weight reduction.

Q-04

How long should I use Retatrutide?

Most users use it for 3–6 months to reach their goal weight, then either discontinue (with lifestyle changes to maintain) or continue at a lower maintenance dose. Weight typically returns if discontinued without behavioral changes.

§ 09

Where to get Retatrutide in the Philippines

Retatrutide is not available at any Filipino pharmacy or clinic — it remains a Phase 3 investigational compound globally. Research-grade sourcing is the only path. For Philippines pricing, supplier verification, and COA red flags, see our Retatrutide Philippines 2026 guide. For the legal status of research peptides in the Philippines, see our legality guide. Then browse the community-verified supplier list.

Retatrutide Philippines 2026 Guide Community Supplier List

Primary sources

Citations supporting the clinical claims on this page. Each entry links to the primary record.

[01]
Retatrutide Phase 2 — obesity
Trial
Jastreboff AM et al. "Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial." N Engl J Med 2023;389:514-526.
DOI: 10.1056/NEJMoa2301972
[02]
Retatrutide Phase 2 — type 2 diabetes
Trial
Rosenstock J et al. "Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial." Lancet 2023;402(10401):529-544.
DOI: 10.1016/S0140-6736(23)01053-X
[03]
Retatrutide MASLD trial
Trial
Sanyal AJ et al. "Triple Hormone Receptor Agonist Retatrutide for Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomized Phase 2a Trial." Nat Med 2024;30:2037-2048.
DOI: 10.1038/s41591-024-03018-2
[04]
TRIUMPH-1 / TRIUMPH-3 — Phase 3 protocols
Trial
Eli Lilly. "A Study of Retatrutide (LY3437943) in Adult Participants With Obesity and Hypertension." ClinicalTrials.gov NCT05882045.
Source
[05]
Triple-agonist mechanism review
Mechanism
Coskun T et al. "LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycaemic control and weight loss: From discovery to clinical proof of concept." Cell Metab 2022;34(9):1234-1247.e9.
DOI: 10.1016/j.cmet.2022.07.013

Risk · Disclosure · Editorial Status

This page is editorial information for adults researching peptide therapy. It is not medical advice, not a prescription, and not an endorsement of any specific product, supplier, or protocol. Side effects can be serious and individual response varies. Talk to a licensed physician — ideally one with peptide-specific clinical experience — before starting any compound, adjusting a dose, or discontinuing therapy.

In the Philippines, GLP-1 medications are prescription-only under FDA Philippines regulation. Research-grade peptides occupy a regulatory gray area: import for personal research use is generally tolerated, but the Bureau of Customs reserves the right to inspect and detain shipments. Do not import for resale.

Editorial Status

Independent · Non-clinical

Affiliation

Not a clinic · Not a pharmacy

Last Updated

May 7, 2026

↗ Related peptides

Tirzepatide Semaglutide Cagrilintide Mazdutide

↗ Related guides